News

GSK, partner iTeos scrap development of lung cancer therapy
Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...
BioSpace1h
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Failures
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...
Pharmaceutical Technology4h
GSK and iTeos drop anti-TIGIT drug following trial failure
This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.
Medical Dialogues4h
GSK, partner iTeos end development programme for lung cancer drug belrestotug
GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...
The Business Times5h
GSK to buy liver disease drug for as much as US$2 billion
LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker ...
Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14
The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 ...
Explore more
Fierce Biotech23h
GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...
GSK slips Tuesday, underperforms market
GSK PLC closed 25.53% below its 52-week high of £18.24, which the company reached on May 16th.